Accession Number:

ADA416710

Title:

The Clinical Development of Thalidomide as an Angiogenesis Inhibitor Therapy for Prostate Cancer

Descriptive Note:

Annual rept. 28 Sep 2001-27 Sep 2002

Corporate Author:

MD ANDERSON CANCER CENTER SMITHVILLE TXSCIENCE PARK RESEARCH DIV

Personal Author(s):

Report Date:

2002-10-01

Pagination or Media Count:

113.0

Abstract:

The purpose of this award is to evaluate the 1 Safety and toxicity of neo-adjuvant thalidomide therapy prior to radical prostatectomy in patients with locally advanced prostate carcinoma PCa, assessed by wound healing and peri-operative bleeding 2 Efficacy of neo-adjuvant thalidomide treatment, as measured by the rate of tumor reduction I PSA decline while on thalidomide therapy 3 Qualitative measurements of the in vivo effect of thalidomide therapy on the Endothelial and Epithelial compartment PCa cells.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE